VRTX240906C487500
- 3.50
- 0.000.00%
Vertex Pharmaceuticals Newsroom
Evercore Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $515
Maxim Group Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating
Vertex Pharmaceuticals: A Cautious Hold Amidst Mixed Financial Signals and Pipeline Uncertainty
Redburn Atlantic Adjusts Price Target on Vertex Pharmaceuticals to $560 From $545
HC Wainwright & Co. Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $600
Vertex Downgraded at Barclays Due to Valuation
Oppenheimer Initiates Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Announces Target Price $550
Truist Financial Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Announces Target Price $550
Vertex Pharmaceuticals (VRTX) Gets a Buy From Truist Financial
Vertex Pharmaceuticals Price Target Raised to $509.00/Share From $472.00 by Barclays
JPMorgan Adjusts Price Target on Vertex Pharmaceuticals to $510 From $505, Maintains Overweight Rating
Barclays Downgrades Vertex Pharmaceuticals(VRTX.US) to Hold Rating, Raises Target Price to $509
Analysts' Opinions Are Mixed on These Healthcare Stocks: Adaptimmune Therapeutics (ADAP), Lantheus (LNTH) and Vertex Pharmaceuticals (VRTX)
Analyst Issues Sell Rating on Vertex Pharmaceuticals Amid Maturing CF Products and Overvalued Pain Franchise
Buy Rating on Vertex Pharmaceuticals: Uncovering the Market Potential of Novel Pain Treatments
Buy Rating Reaffirmed for Vertex Pharmaceuticals Amid Strong Performance and Promising Pipeline
Evercore Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Announces Target Price $515
Vertex Pharmaceuticals Analyst Ratings
A Quick Look at Today's Ratings for Vertex Pharmaceuticals(VRTX.US), With a Forecast Between $515 to $600
Evercore ISI Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX)